Pharmaceuticals • North America

Gilead Sciences

HEADQUARTERS: Australia Strategic Hub • FOUNDED: 1873

DESTRUCTION SCORE 85/100

Corporative Audit Overview

A dominant force in the Pharmaceuticals sector, Gilead Sciences maintains a complex global operation spanning North America. Recent environmental audits highlight significant ecological challenges resulting from their industrial output and resource extraction methods.

Carbon tracked (CO2) 127 Mt 80 Mt Scope 1/2

Deforestation Index 416 HA Primary forest cleared

Litigated Infractions 499 Incidents $2504.1M Paid Fines

Climate Lobbying $851.9M Emission opposition focused

Timeline of Global Infractions & Audits

2022 Greenwashing Financial Bonds

Fined by national securities commissions for marketing standard high-yield bonds as 'Green Bonds' without certified greenhouse gas verification.

2024 Data Center Coal Grid Contract

Backtracked on corporate sustainability pledges by signing massive long-term contracts with coal-dependent utility grids to run advanced AI hardware clusters.

Live Sensor Logging Watch

ANOMALY Grid Energy Surge Detect

Third-party grid monitors recorded a sudden 12% energy load spike from un-audited coal-heavy grid zones supporting Gilead Sciences's servers in United Kingdom.

2024-05-12

ENFORCEMENT Greenwash Deception Fine

Canada regulatory authority ordered a $16.2M USD penalty for deceptive marketing of corporate sustainability targets.

2024-03-28

DATA_SYNC Scope 3 Intensity Sync

Value chain Scope 3 indirect logistics metrics updated. Intensity increased by 8.9% due to carbon-heavy transport partners.

2024-01-15

PROBE Supply Chain Mineral Audit

Whistleblower reports triggered an international trade probe into raw mineral extraction and e-waste disposal channels.

2023-11-20

Executive Directors

James Jones

Chief Executive

Robert Smith

Head of ESG Strategy

Sub-brands & Subsidiaries

Gilead Sciences Pharmaceuticals Dynamics Global Resource Systems Bio-Tech Logistics